HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Delay For Sanofi’s OTC Cialis Study In US Could Be Sign of Hurdles Holding Back Other Switches

Executive Summary

Potential hurdles FDA put in front of Sanofi’s planned tadalafil switch could be sign for agency’s expectations for moving other Rx ingredients to OTC. Sanofi announced its planned actual use trial to support OTC tadalafil use was “placed on clinical hold due to matters surrounding the protocol design.”

You may also be interested in...



Sanofi Hopes UK Cialis Launch Will Illustrate US Switch Potential

Sanofi's upcoming launch of OTC Cialis in the UK is quite important for getting a sense of what the over-the-counter opportunity could be and the appetite [in the US],” according to company CEO Paul Hudson.

Sanofi Sees Tough Economic Environment Start To Temper Demand

Sanofi Consumer Healthcare is starting to feel the effects of the tough economic environment, with signs of "growth moderation" in recent months. While the firm's global Q3 sales advanced by almost 2%, turnover in the US was hit by a "broad market slowdown."

Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut

Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel